Navigation Links
EntreMed ENMD-2076 Phase 2 Data to Be Presented at ASCO Annual Meeting
Date:5/19/2011

ROCKVILLE, Md., May 19, 2011 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced the presentation of clinical data for its Phase 2 study with ENMD-2076 in platinum-resistant ovarian cancer patients.  The data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting to be held June 3 - 7, 2011 in Chicago, Illinois.

(Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO)-

Gynecologic Cancer Track: Poster SessionFriday, June 3, 2011 – 2:00 p.m. - 6:00 p.m. (CDT) Abstract No.: 5021Title: A Phase 2 Study of ENMD-2076 in platinum-resistant ovarian cancer Poster Board: 10, Location: E450aDiscussion SessionFriday, June 3, 2011 – 5:00 p.m. - 6:00 p.m. (CDT)Location: E354bAbout ENMD-2076ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. Preclinical studies with ENMD-2076 demonstrated significant antitumor activity, including tumor regression, in multiple solid and hematological malignancies. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers. While ENMD-2076 is currently in a Phase 2 trial in ovarian cancer, preclinical and clinical activities are ongoing in assessing the compound's applicability in other forms of cancer.

About EntreMedEntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer.  
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
4. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
5. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
6. EntreMed to Present at The New York Society of Security Analysts Industry Conference
7. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
8. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
9. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
10. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
11. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013  Boston Scientific Corporation (NYSE: BSX ... Scientific Program May 21-24 in Paris ... particularly rich and diversified set of data this year ... M.D., global chief medical officer, Boston Scientific.  "The primary ... the NG PROMUS trial, which evaluated our Promus PREMIER ...
(Date:5/16/2013)... and MECHELEN, Belgium , May 17, ... (NYSE: ABBV ) announced today an extension ... disease.  Galapagos will fund and complete a Phase 2 ... rapid progression into Phase 3.  Upon successful completion of ... Galapagos $50 million.  The terms of the collaboration extension ...
(Date:5/16/2013)... -- Nektar Therapeutics, (Nasdaq: NKTR ) President and Chief ... scheduled to present at the upcoming 2013 UBS Global Healthcare ... Sheraton New York Hotel on Tuesday, May 21, 2013 at ... accessible via a Webcast through a link posted in the ... http://www.nektar.com . This Webcast will be available for replay until ...
Breaking Medicine Technology:Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 2AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 4AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 5AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 6Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City 2
... INTERIM DATA FROM PHASE 3 CLINICAL TRIAL FOR NATURLOSE(R) ... (Nasdaq: SPEX ), an innovator in biotechnology ... to food, supplement, biotechnology and pharmaceutical companies, today announced ... Previously scheduled for May, the meeting will instead be ...
... CSL Behring has been informed by the U.S. Food ... first FDA-approved treatment of acute bleeding episodes in patients ... seven years of orphan-drug exclusivity. RiaSTAP was approved ... the treatment of acute bleeding episodes in patients with ...
Cached Medicine Technology:Spherix Postpones 2009 Annual Shareholders Meeting to Share Interim Diabetes Clinical Trial Data 2Spherix Postpones 2009 Annual Shareholders Meeting to Share Interim Diabetes Clinical Trial Data 3CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency 2CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency 3CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency 4
(Date:5/18/2013)... Simple changes in a person’s every day ... more water can lead to substantial health benefits, the ... overall. Diet Doc understands that overcoming significant ... be difficult and often requires the use of prescription ... patients get over initial weight loss hurdles. In addition ...
(Date:5/18/2013)... May 18, 2013 Show And Go Training, ... various different training systems that is all about is getting ... the attention of http://ShowAndGoTrainingReview.com ’s Stan Stevenson, prompting ... is a unique “four phase system” designed to make you ... of time spent working out in the gym. The training ...
(Date:5/18/2013)... The American Society for Dermatologic Surgery ... (D) to sign a bill (HB 2896) that would ... age of 18 from tanning indoors. , With Gov. ... the nation to enact an under-18 tanning ban. California ... for minors. Nationwide, 34 states and the District of ...
(Date:5/18/2013)... Scott Tischler of Tischler Brothers Fitness helped ... keys to losing weight played a huge part in Troy ... Tischler, Troy was able to lose a pound a day. ... should be approached with caution and any activity should be ... keys to weight loss that Scott Tischler advocates. With these ...
(Date:5/18/2013)... New York, NY (PRWEB) May 18, 2013 ... now available at Condomania, America’s favorite condom store recently ... sampler packs to the store's large selection of condoms ... condoms sampler packs make it easy to try different ... on the market. Featuring Kimono’s classic comfortable shape ...
Breaking Medicine News(10 mins):Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announce the Best Weight Loss Through New Whole Foods, Healthy Snacks and Prescription Strength hCG Treatments 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announce the Best Weight Loss Through New Whole Foods, Healthy Snacks and Prescription Strength hCG Treatments 3Health News:Show And Go Training: Review Examining Eric Cressy's Workout Program Revealed 2Health News:ASDSA Urges Oregon Governor to Sign Under-18 Indoor Tanning Restrictions 2Health News:Kimono Condoms Assorted Sampler Packs Now Available at Condomania 2
... The cold and flu season is upon us again. This year ... flu and some will even die from it. The latest victim ... small firm in Phoenix, Arizona comes to the rescue. This firm, ... cold and flu products. Unlike all of the competing cold and ...
... have countless conversations with ourselves, and if we really listen ... to ourselves is critical, judgmental, and often unforgiving. We seem ... tend to make excuses and blame others, or we blame ... shortcomings. Carol Messmer,s new book, "Conversations with ...
... Care Guidelines will be used to Combat Waste in ... permanent Recovery Audit Contractor (RAC) for the Centers for ... license agreement with Milliman Care Guidelines (R). ... and software to review Medicare claims. HDI is the ...
... March 3 /PRNewswire-FirstCall/ -- The Providence ... announced that Avalon Correctional Services (Pink Sheets: CITY) ... against Providence. "We are delighted that Avalon and ... recognized that continuing their consent solicitation is not ...
... Minnesota Dance and Exercise Entrepreneur Releases 15 Original ... 3 Dancercise Kids(R), a provider of unique ... announced that its founder, Tessa Pfeifer, has released ... on bringing Dancercise(R) concepts into every home.Packed with ...
... a Grant from Otsuka America Pharmaceutical, Inc.ROCKVILLE, Md., March ... three universities as the recipients of Helping Hands Grants. ... to $5,000 for a community mental health service project ... of medical faculty. The awards are made possible ...
Cached Medicine News:Health News:Discovery Yields Cure for the Common Cold and the Flu 2Health News:'Conversations with Self: Discovering the Power of Your Inner Voice': Discover How to Find and Listen to an Inner Voice That Is Encouraging and Helpful 2Health News:Recovery Audit Contractor HealthDataInsights Licenses Milliman Care Guidelines(R) 2Health News:Recovery Audit Contractor HealthDataInsights Licenses Milliman Care Guidelines(R) 3Health News:Providence Service Corporation Announces That Avalon Correctional Services Has Abandoned Its Consent Solicitation 2Health News:Providence Service Corporation Announces That Avalon Correctional Services Has Abandoned Its Consent Solicitation 3Health News:Providence Service Corporation Announces That Avalon Correctional Services Has Abandoned Its Consent Solicitation 4Health News:New Kids' CD Encourages Kids to Get Active and Stay Healthy 2Health News:American Psychiatric Foundation Announces Recipients of Helping Hands Grants 2Health News:American Psychiatric Foundation Announces Recipients of Helping Hands Grants 3
Finesse II electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
The Aaron 800-EU is designed and engineered to be the most reliable and durable desiccator available today....
Sabre 180 is a powerful niche generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Medicine Products: